-- Scott Roberts
MONDAY, March 31, 2014 (HealthDay News) The drug Alprolix has
been approved by the U.S. Food and Drug Administration as the first
long-acting hemophilia B clotting agent, the FDA said in a news
The product, formally known as "coagulation factor IX
recombinant Fc Fusion protein" is the first hemophilia B remedy
designed to require less frequent injections than prior treatments,
the FDA said. It was approved to help control and prevent bleeding
episodes and to manage bleeding during surgery.
Hemophilia B is a blood-clotting disorder, primarily affecting
males, caused by an abnormal Factor IX gene. Affecting some 3,300
people in the United States, it can lead to potentially deadly
Alprolix was evaluated in clinical studies involving 123 people,
ages 12-71, with severe hemophilia B. No safety issues were
identified during the trials, the FDA said.
The product is manufactured by Biogen Idec, located in
Visit the National Hemophilia Foundation to learn more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.